title: Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
abstract: The use of rifamycins is limited by drug interactions in human immunodeficiency virus (HIV)-infected persons who are receiving highly active antiretroviral therapy (HAART). During a tuberculosis (TB) outbreak at a prison housing HIV-infected inmates, rifabutin was used to treat 238 men (13 case patients and 225 contacts). Steady-state peak plasma rifabutin concentrations were obtained after rifabutin dosages were adjusted for men receiving single-interacting HAART (with either 1 protease inhibitor [PI] or efavirenz), multi-interacting HAART (with either 2 PIs or > or =1 PI with efavirenz), and for noninteracting HAART (>1 nucleoside reverse-transcriptase inhibitor or no HAART) without rifabutin dose adjustments. Low rifabutin concentrations occurred in 9% of those receiving noninteracting HAART, compared with 19% of those receiving single-interacting and 29% of those receiving multi-interacting HAART (chi2, 3.76; P=.05). Of 225 contacts treated with rifabutin-pyrazinamide, 158 (70%) completed treatment while incarcerated. Rifabutin-pyrazinamide therapy was difficult to implement, because of the need for dosage adjustments and expert clinical management.
authors.affiliation: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. pps9@cdc.gov
authors.forename: P
authors.initials: P
authors.lastname: Spradling
authors.forename: D
authors.initials: D
authors.lastname: Drociuk
authors.forename: S
authors.initials: S
authors.lastname: McLaughlin
authors.forename: L M
authors.initials: LM
authors.lastname: Lee
authors.forename: C A
authors.initials: CA
authors.lastname: Peloquin
authors.forename: K
authors.initials: K
authors.lastname: Gallicano
authors.forename: C
authors.initials: C
authors.lastname: Pozsik
authors.forename: I
authors.initials: I
authors.lastname: Onorato
authors.forename: K G
authors.initials: KG
authors.lastname: Castro
authors.forename: R
authors.initials: R
authors.lastname: Ridzon
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004196:Disease Outbreaks; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007325:Institutional Practice; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011329:Prisoners; D017828:Rifabutin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology*
chemical_list: D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D017828:Rifabutin